The treat-to-target paradigm: A cross-sectional survey of current therapies and achieved metabolic control in 800 type 2 diabetic patients

被引:5
作者
Buysschaert, M [1 ]
Hermans, MP [1 ]
机构
[1] Catholic Univ Louvain, Clin Univ St Luc, Serv Endocrinol & Nutr, B-1200 Brussels, Belgium
关键词
treatment; glycaemic control; lipids; blood pressure;
D O I
10.1179/acb.2005.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of this cross-sectional study is to analyse the current treatment schemes as well as the quality of control (metabolic; blood pressure) in a cohort of 800 type 2 diabetic patients recruited in a University Center and not by generalist practionners, in scope with current international recommendations. Insulin therapy was administered, alone or combined with oral antihyperglycaemic drugs, to 48% of subjects. HbA(1)c was 7.7% (6.7-8.7 (median; percentiles 25-75)). Anti-dyslipidaemic drugs were used in 45% of individuals. However, only 27% of the cohort had LDL levels lower than 100 mg/dl while 58% of males and 48% of females attained HDL targets. Systolic and diastolic blood pressure levels were 144 +/- 21 and 81 +/- 12 mmHg (mean +/- SD), despite one or more antihypertensive agent(s) prescribed to 68% of subjects. In conclusion, 79 in a Belgian adult type 2 diabetic population attending a tertiary centre for follow-up, overall metabolic and blood pressure controls remain unsatisfactory according to targets defined by international guidelines. This audit makes a multi-faceted intervention aimed at intensifying current therapies all the more necessary.
引用
收藏
页码:79 / 85
页数:7
相关论文
共 42 条
[1]   2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension [J].
Afridi, I ;
Canny, J ;
Yao, CH ;
Christensen, B ;
Cooper, RS ;
Kadiri, S ;
Hill, S ;
Kaplan, N ;
Kuschnir, E ;
Lexchin, J ;
Mendis, S ;
Poulter, N ;
Psaty, BM ;
Rahn, KH ;
Sheps, SG ;
Whitworth, J ;
Yach, D ;
Bengoa, R ;
Ramsay, L ;
Kaplan, N ;
Mendis, S ;
Poulter, N ;
Whitworth, J .
JOURNAL OF HYPERTENSION, 2003, 21 (11) :1983-1992
[2]  
*AM DIAB ASS, 2002, IMPLICATIONS UK PROS, V25, pS28
[3]  
*AM DIAB ASS, 2004, DIABETES CARE S1, V27, pS15
[4]  
[Anonymous], 1999, Diabet Med, V16, P716
[5]  
[Anonymous], 2000, Lancet, V355, P253, DOI DOI 10.1016/S0140-6736(99)12323-7
[6]   Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy [J].
Barnett, AH ;
Bain, SC ;
Bouter, P ;
Karlberg, B ;
Madsbad, S ;
Jervell, J ;
Mustonen, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (19) :1952-1961
[7]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[8]   Glycaemic and blood pressure controls achieved in a cohort of 318 patients with type 2 diabetes [J].
Buysschaert, M ;
Hermans, MP .
ACTA CLINICA BELGICA, 1999, 54 (06) :328-333
[9]   Non-pharmacological management of type 2 diabetes [J].
Buysschaert, M ;
Hermans, MP .
ACTA CLINICA BELGICA, 2004, 59 (01) :14-19
[10]   STUDY ON A GROUP OF DIABETICS ENROLLED IN A HOME GLUCOSE MONITORING PROGRAM [J].
BUYSSCHAERT, M ;
LAMBERT, L ;
DONCKIER, J ;
JAMART, J .
ACTA CLINICA BELGICA, 1993, 48 (05) :316-323